,

Moderna Raises Guidance. Your Calls Still Expire Worthless.


The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.

  •   1 min read
Moderna Raises Guidance. Your Calls Still Expire Worthless.

Moderna just raised its 2026 revenue growth outlook to 15% to 25%. The old number was up to 10%. That is a company looking at its own forecast and calling it a typo.

CEO StΓ©phane Bancel credited newer products and geographic diversification. Translation: the Covid shot sold well overseas. Overseas revenue hit $533 million against $780 million in the U.S. Diversification means people in more countries got jabbed.

Q3 revenue rose 29% to $1.31 billion. Analysts expected roughly $890 million. Wall Street's finest missed by about $400 million. These people have Bloomberg terminals and still whiffed. You have a Robinhood account and a hunch from a podcast.

Moderna also posted a $162 million profit, or $0.38 per share, after a $200 million loss a year earlier. The company went from bleeding to earning in twelve months. Your portfolio has been bleeding for a decade and calls it a long-term hold.

The stock jumped on the news. Some of you bought the top. Some of you sold the bottom. A few of you did both on the same day, which takes real talent.

Here is the technical read. A line on a chart went up. Another line will go down. Nothing Bancel said on that call changes the shape of a candlestick.

Moderna says it will grow 15% to 25%. Your account says it will shrink by exactly what you deposit.

Congratulations to the vaccine maker on beating a bar it set itself. You should try that sometime. Set the bar on the floor and step over it. It is the only strategy you have not tried.

Photo by Mufid Majnun on Unsplash

Related Posts

↑

The Noise is free. If Phil's commentary made you laugh or think, he accepts tips. No pressure β€” the sarcasm was complimentary.

Leave a Tip